gilead waives rights to acquire immune-oncology biotech pionyr.

gilead (gild) announces os data on yescarta from zuma-7 study. gilead sciences inc.&rsquo.s gild kite announces positive primary overall survival (os) analysis results of the late-stage zuma-7 study on yescarta.

gileads flagship car t-cell therapy shows improved overall survival in pretreated lymphoma patients. ) company announced the

nurixs (nrix) stock up due to license option exercise by gilead. nurix therapeutics nrix announced that its partnergilead sciences gild has exercised its option to exclusively license the former&rsquo.s investigational targeted protein

kite reports primary overall survival analysis results of phase 3 zuma-7 study. (rttnews) - kite a gilead company (gild) announced the primary overall survival analysis results of the phase 3 zuma-7 study. the results showed a statistically sig

gilead exercises first license option under agreement with nurix therapeutics.

gilead exercises first license option under agreement with nurix therapeutics.

gilead sciences unusual options activity. someone with a lot of money to spend has taken a ish stance on ). and retail traders should know. we noticed this today when the big position showed up on publicly available options history that we track here at

gilead sciences inc. (gild) presents at barclays 2023 global healthcare conference (transcript).

gilead sciences inc. (gild) presents at cowen 43rd annual healthcare conference (transcript).

peering into gilead sciencess recent short interest. ) short percent of float has risen 3.28% since its last report. the company recently reported that it has

gilead sciences touts encouraging data from real world studies of its flagship covid-19 treatment. )from three retrospective real-world veklury (rem

gilead : phase 2 data show benefit of trodelvy across multiple types of metastatic urothelial cancer. (rttnews) - gilead sciences inc. (gild) announced a positive results from three cohorts of the phase 2 trophy-u-01 study of trodelvy (sacituzum

gilead sciences reaches analyst target price. in recent trading shares of gilead sciences inc (symbol: gild) have crossed above the average analyst 12-month target price of $86.12 changing hands for $86.36/share. when a stock reaches the target

gileads (gild) breast cancer drug trodelvy gets fda nod. gilead sciences inc.gild announced the approval of sacituzumab govitecan-hziy by the fda for the treatment of metastatic hormone receptor (hr)-positive human epidermal growth fac

gilead (gild) q4 earnings & sales top on biktarvy & oncology. gilead sciences inc. gild reported better-than-expected fourth-quarter results driven by continued solid demand for its hiv portfolio with further share growth for flagship

gilead sciences trovelvy scores fda approval for advanced/metastatic breast cancer setting. the

gileads breast cancer drug secures United States fda approval for expanded use. gilead sciences inc said on friday the United States food and drug administration had greenlighted expanded use of trodelvy to treat the most common type of breast c

nasdaq 100 movers: team gild. in early trading on friday shares of gilead sciences topped the list of the days best performing components of the nasdaq 100 index trading up 3.8%. year to date gilead sciences has lost about 1.6% of its value

gilead sciences posts better-than-expected q4 earnings 2023 profit mid-point guidance above estimates.

gilead sciences raises dividend by 2.7% to $0.75.

gilead q4 net income soars 334% yoy helped by massive decline in cost of goods sold.

gilead sciences inc. q4 profit increases beats estimates. (rttnews) - gilead sciences inc. (gild) reported earnings for its fourth quarter that increased from the same period last year and beat the street estimates.

gilead profit beats street expectations on covid and hiv sales. gilead sciences inc on thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its hiv and cancer drugs while covid-19 antiviral veklury had sales

gilead issues unexpectedly ish outlook after cancer drug sales rocket.

why gilead (gild) is poised to beat earnings estimates again. if you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report you should

gilead arcellx close agreement on developing t-cell therapy for multiple myeloma.

gilead sciences pt raised to $85 at ubs.

gilead sciences (gild) presents at the j.p. morgan 41st annual healthcare conference - slideshow.

gilead looks fully valued for 2023.